Navigation Links
Tulane Cancer Center to begin novel clinical trial for late-stage prostate cancer drug
Date:11/17/2009

International prostate cancer expert Dr. Oliver Sartor of Tulane Cancer Center is the first oncologist in the United States to offer patients an experimental new treatment for late-stage prostate cancer through a multi-center clinical trial that is currently recruiting patients at 100 sites across 20 countries worldwide.

The Cancer Center is seeking patients with advanced prostate cancer that has spread to the bones to take part in a phase III randomized clinical trial for Alpharadin (pronounced "Alpha-raydin"), an injectable treatment based on the radioactive substance Radium-223, an alpha-particle emitting pharmaceutical. All participants will receive the best available standard therapy and are randomized so that two-thirds of the subjects receive Alpharadin in addition. The other third of subjects will receive placebo along with the standard of care therapy. Early clinical trials of Alpharadin have suggested that it is well tolerated and that it might prolong survival for men whose prostate cancer is no longer responding to hormone therapy and has spread to the bones.

"Alpharadin appears to work by targeting and destroying cancer cells in the bone while sparing healthy bone marrow tissue," said Sartor, Piltz Professor of Cancer Research in the Departments of Medicine and Urology at Tulane University School of Medicine. "If successful in clinical trials, this compound could make a significant difference for the large number of men whose cancer has spread to the bones. Patients most often die as a consequence of the metastases not the primary cancer so preventing cancer from spreading and controlling cancer that has spread is a major clinical challenge."

According to the American Cancer Society, prostate cancer is the most frequently diagnosed cancer in men in the United States, affecting approximately one in six men each year; approximately 192,000 new cases will be diagnosed in 2009. Approximately 27,000 men in the United States die from prostate cancer each year and about 90 percent of these men have bone metastases.

Treatment options for men with metastatic prostate cancer of the bones are limited, and life expectancy, if left untreated, is an average 12 to 18 months. In addition, bone metastases can be very debilitating. Typically, patients with bone metastases experience severe bone pain, which increases as the metastasis grows, as well as other serious complications including neurological symptoms, fractures, severe anemia, or spinal cord compression. These complications can decrease patient quality of life and shorten life expectancy.


'/>"/>

Contact: Keith Brannon
kbrannon@tulane.edu
504-862-8789
Tulane University
Source:Eurekalert

Related medicine news :

1. High alcohol consumption increases stroke risk, Tulane study says
2. Tulane University to receive $14M for international HIV/AIDS program
3. Ruths Hospitality Group Inc. donates Broad Street building to Tulane
4. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
5. Survival differences by race most apparent in advanced stages of breast cancer
6. MRI finds breast cancer before it becomes dangerous
7. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
8. Pathway links inflammation, angiogenesis and breast cancer
9. Radiologists encouraged to look beyond cancer for clinically unseen diseases
10. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
11. Immune deficiency linked to a type of eye cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... ... 24, 2016 , ... Those who have experienced traumatic events may suffer from ... avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid this ... coping following a traumatic event. , Trauma sufferers tend to feel a range of ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
Breaking Medicine Technology: